Diferenças de sexo na eficácia, segurança e persistência de pacientes com artrite psoriática tratados com tofacitinibe: Uma análise post hoc de ensaios de fase 3 e extensão a longo prazo
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.